Inhibition of phosphoinositide 3‑kinase/Akt pathway decreases hypoxia inducible factor‑1α expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells

Zhang,Jing; Guo,Hua; Zhu,Jin‑Shui; Yang,Yu‑Chen; Chen,Wei‑Xiong; Chen,Ni‑Wei

doi:10.3892/ol.2014.1963

Inhibition of phosphoinositide 3‑kinase/Akt pathway decreases hypoxia inducible factor‑1α expression and increases therapeutic efficacy of paclitaxel in human hypoxic gastric cancer cells

Authors:
- Jing Zhang
- Hua Guo
- Jin‑Shui Zhu
- Yu‑Chen Yang
- Wei‑Xiong Chen
- Ni‑Wei Chen
View Affiliations

Affiliations: Department of Gastroenterology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: March 11, 2014 https://doi.org/10.3892/ol.2014.1963
Pages: 1401-1408

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The phosphatidylinositol‑3‑kinase (PI3K)̸Akt signaling pathway plays an important role in cell proliferation, transformation, apoptosis, tumor growth and angiogenesis. Paclitaxel is commonly used to treat multiple human malignancies; however, the underlying mechanisms of paclitaxel in gastric cancer (GC) have not been fully investigated. In the present study, specimens from 45 GC and 36 chronic gastritis patients were collected, and the correlations of PI3K, phosphorylated‑Akt (p‑Akt) and hypoxia‑inducible factor‑1α (HIF‑1α) expression with the clinicopathological characteristics of GC were analyzed by immunohistochemistry. The human SGC‑7901 GC cells under hypoxic conditions were pretreated with the PI3K inhibitor, LY294002 (40 µM), and paclitaxel (0.1 µM). The expression levels of PI3K, p‑Akt and HIF‑1α were detected by quantitative polymerase chain reaction and western blotting. Cell proliferative activity and apoptosis were evaluated by the Cell Counting Kit‑8 assay and flow cytometry. As a result, the rates of positive expression of PI3K, p‑Akt and HIF‑1α were significantly higher in GC compared with chronic gastritis patients (each P<0.01), and were positively associated with the tumor‑node‑metastasis (TNM) staging, lymph node metastases, lymphatic infiltration and vascular infiltration (each P<0.01), but inversely correlated with tumor differentiation (P<0.01) in patients with GC. Under hypoxic conditions, the combined inhibition of the PI3K̸Akt pathway with paclitaxel markedly reduced the proliferative activity and induced cell apoptosis in GC cells compared with the single treatment of PI3K inhibitor or paclitaxel (each P<0.01), and was accompanied by a decreased expression of HIF‑1α. Overall, our findings indicate that the increased expression of the PI3K̸Akt̸HIF‑1α pathway was closely correlated with tumor differentiation, TNM staging, lymph node metastases and lymphatic and vascular infiltration. The inhibition of the PI3K̸Akt pathway enhanced the therapeutic efficacy of paclitaxel in GC cells under hypoxic conditions, suggesting that the PI3K̸Akt̸HIF‑1α pathway may act as an important therapeutic target for paclitaxel treatment of GC.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Tajima Y, Yamazaki K, Makino R, et al: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res. 12:6469–6479. 2006. View Article : Google Scholar
3	Li Q and Yang Z: Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res. 28:652009. View Article : Google Scholar : PubMed/NCBI
4	Uegaki K, Kanamori Y, Kigawa J, et al: PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep. 14:389–392. 2005.
5	Sun ZJ, Chen G, Hu X, et al: Activation of PI3K/Akt/IKK-alpha/NF-kappaB signaling pathway is required for the apoptosis-evasion in human salivary adenoid cystic carcinoma: its inhibition by quercetin. Apoptosis. 15:850–863. 2010. View Article : Google Scholar
6	Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI
7	Xue G, Restuccia DF, Lan Q, et al: Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes. Cancer Discov. 2:248–259. 2012.PubMed/NCBI
8	Valkov A, Kilvaer TK, Sorbye SW, et al: The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. J Transl Med. 9:2002011. View Article : Google Scholar : PubMed/NCBI
9	Lee GW, Go SI, Cho YJ, et al: Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study. J Thorac Oncol. 7:528–534. 2012.
10	Park S, Ha SY, Cho HY, et al: Prognostic implications of hypoxia-inducible factor-1α in epidermal growth factor receptor-negative non-small cell lung cancer. Lung Cancer. 72:100–107. 2011.
11	Argyriou P, Papageorgiou SG, Panteleon V, et al: Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1→HIF-1α pathway. Ann Hematol. 90:315–322. 2011.PubMed/NCBI
12	Mottet D, Dumont V, Deccache Y, et al: Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem. 278:31277–31285. 2003. View Article : Google Scholar
13	Koshikawa N, Hayashi J, Nakagawara A and Takenaga K: Reactive oxygen species-generating mitochondrial DNA mutation up-regulates hypoxia-inducible factor-1alpha gene transcription via phosphatidylinositol 3-kinase-Akt/protein kinase C/histone deacetylase pathway. J Biol Chem. 284:33185–33194. 2009. View Article : Google Scholar
14	Xu K, Ding Q, Fang Z, et al: Silencing of HIF-1alpha suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis. Cancer Gene Ther. 17:212–222. 2010. View Article : Google Scholar : PubMed/NCBI
15	Tanaka H, Yamamoto M, Hashimoto N, et al: Hypoxia-independent overexpression of hypoxia-inducible factor 1alpha as an early change in mouse hepatocarcinogenesis. Cancer Res. 66:11263–11270. 2006. View Article : Google Scholar
16	Fang J, Ding M, Yang L, et al: PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 19:2487–2497. 2007. View Article : Google Scholar : PubMed/NCBI
17	Shi Y, Chen L, Li J, et al: Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol. 32:381–390. 2011. View Article : Google Scholar
18	McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
19	Liang K, Lu Y, Li X, et al: Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol. 70:1045–1052. 2006. View Article : Google Scholar
20	Abrams SL, Steelman LS, Shelton JG, et al: Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy. Cell Cycle. 9:1839–1846. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang Y, Liu X, Zhang J, et al: The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer. Oncol Lett. 4:763–766. 2012.PubMed/NCBI
22	Kim JG, Chae YS, Sohn SK, et al: Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer. Oncology. 79:278–282. 2010. View Article : Google Scholar : PubMed/NCBI
23	Isobe T, Aoyagi K, Koufuji K, et al: Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer. Int J Clin Oncol. 18:293–304. 2013.
24	Hu L, Hofmann J, Lu Y, et al: Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62:1087–1092. 2002.
25	Xu R, Nakano K, Iwasaki H, et al: Dual blockade of phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer. Cancer Lett. 306:151–160. 2011.
26	Kim SH, Juhnn YS and Song YS: Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
27	Zeng L, Kizaka-Kondoh S, Itasaka S, et al: Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci. 98:1394–1401. 2007. View Article : Google Scholar : PubMed/NCBI
28	Fekete M, Santiskulvong C, Eng C and Dorigo O: Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Res. 32:445–452. 2012.PubMed/NCBI
29	Shafee N, Kaluz S, Ru N and Stanbridge EJ: PI3K/Akt activity has variable cell-specific effects on expression of HIF target genes, CA9 and VEGF, in human cancer cell lines. Cancer Lett. 282:109–115. 2009. View Article : Google Scholar : PubMed/NCBI
30	Zhong H, Chiles K, Feldser D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541–1545. 2000.
31	Jiao M and Nan KJ: Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.
32	Manohar SM, Padgaonkar AA, Jalota-Badhwar A, et al: A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells. BMC Cancer. 11:3382011.